ImmuneRegen BioSciences, Inc. Appoints Investor Awareness, Inc. to Launch Investor Relations Program
18 Luglio 2006 - 5:50PM
PR Newswire (US)
SCOTTSDALE, Ariz., July 18 /PRNewswire-FirstCall/ -- ImmuneRegen
BioSciences, Inc. (OTC:IRBO) (BULLETIN BOARD: IRBO) , a wholly
owned subsidiary of IR BioSciences Holdings, Inc., today announced
it has retained the services of Investor Awareness, Inc. as its
investor relations firm. Chicago-based Investor Awareness, Inc., a
full service investor and media relations consulting firm, provides
private and publicly traded companies with customized programs to
generate awareness among members of the financial community.
Investor Awareness specializes in accelerating the growth in the
value of small to midsize companies. Tony Schor, President of
Investor Awareness, Inc., said, "We are pleased to work on behalf
of ImmuneRegen BioSciences, Inc. during this exciting phase of
their growth and development. With the Company's recent
announcement of its agreement with the National Institutes of
Health's (NIH) National Institute of Allergy and Infectious
Diseases (NIAID) component to fund and conduct a preclinical
anti-microbial evaluation of ImmuneRegen's proprietary compound
Viprovex(TM) for potential use as a possible treatment for certain
infectious respiratory diseases including influenza, measles and
SARS, the timing is perfect to communicate the company's compelling
story to the investment community." "Investor Awareness, Inc. will
play an integral role in ensuring we reach the investment community
with our message," said Michael Wilhelm, President of ImmuneRegen
BioSciences, Inc. "We believe that Investor Awareness, Inc. is
uniquely qualified to represent us in view of our anticipated
progress and growth. We have had the opportunity to work in the
past with the Company and its management team and have continued to
monitor its expansion of relationships and the advancement of their
propriety research. It is with this in mind that we are confident
the time is right for us to effectively generate awareness and
convey the Company's strategy for continued growth." About
ImmuneRegen BioSciences, Inc. IR BioSciences Holdings Inc., through
its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a
development stage biotechnology company focused on the research and
development of Homspera(TM) and its derivatives Radilex(TM) and
Viprovex(TM), which are designed to be used as countermeasures for
multiple homeland security bioterrorism threats. Homspera is
derived from modified Substance P, a naturally occurring peptide
immunomodulator and homeostatic compound with the dual effect of
improving pulmonary function and the stimulation of the human
immune system. For more information, please visit the company's
website at http://www.immuneregen.com/. Statements about the
Company's future expectations, including statements about the
potential for the Company's drug candidates, science and
technology, and all other statements in this press release other
than historical facts, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. The
Company intends that such forward-looking statements be subject to
the safe harbors created thereby. These future events may not occur
as and when expected, if at all, and, together with the Company's
business, are subject to various risks and uncertainties. The
Company's actual results could differ materially from expected
results as a result of a number of factors, including the fact that
preliminary results involved only a small number of test mice, the
uncertainties inherent in research and development collaborations,
pre-clinical and clinical trials and product development programs,
(including, but not limited to the fact that future results or
research and development efforts may prove less encouraging than
current results or cause side effects not observed in current
pre-clinical trials) the evaluation of potential opportunities, the
level of corporate expenditures, capital market conditions, and
others set forth in the Company's periodic report on Form 10-Q for
the three months ended March 31, 2006 as filed with the Securities
and Exchange Commission. There are no guarantees that any of the
Company's proposed products will prove to be commercially
successful. The Company undertakes no duty to update
forward-looking statements. Investor relations: Tony Schor or
Lindsay Kenoe Investor Awareness, Inc. 847-945-2222
http://www.investorawareness.com/ John N. Fermanis, CFO ImmuneRegen
BioSciences, Inc. 480-922-3926 http://www.immuneregen.com/ MEDIA
CONTACT: W. Jason Grimley Spelling Communications 310-477-9500
DATASOURCE: ImmuneRegen BioSciences, Inc. CONTACT: Investor
Relations, Tony Schor or Lindsay Kenoe, both of Investor Awareness,
Inc., +1-847-945-2222, for ImmuneRegen BioSciences, Inc.; or John
N. Fermanis, CFO of ImmuneRegen BioSciences, Inc., +1-480-922-3926;
or Media, W. Jason Grimley of Spelling Communications,
+1-310-477-9500, , for ImmuneRegen BioSciences, Inc. Web site:
http://www.immuneregen.com/ http://www.investorawareness.com/
Copyright